hGH fragment raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
Reviewed 2026-08-01. Anything still debated is marked as such rather than presented as settled.
The fragment includes residues that can form an internal disulfide bond between two cysteine positions. This structural feature can influence how the peptide folds and how stable it is in solution. AOD-9604 differs from full-length hGH in size and receptor interactions; it does not contain the entire growth hormone sequence. Published descriptions sometimes use slightly different residue numbering, so sequence information should be checked against primary sources. The molecule is small compared with intact hGH, which affects analytical detection and purification approaches.
Interest in AOD-9604 arose from attempts to separate metabolic effects from growth effects attributed to hGH. Early work explored whether the fragment could influence lipolysis or fat oxidation without promoting growth. Those questions remain partly unresolved because human data are limited and results have varied across studies. The peptide is not a hormone replacement for hGH and is not equivalent to hGH in clinical use. Its research history includes both laboratory studies and commercial marketing claims that are not the same as regulatory approval.
AOD-9604 is a synthetic peptide whose structure corresponds to a C-terminal segment of human growth hormone. It is often described as hGH fragment 176-191, a 16-amino-acid sequence. The peptide was designed to isolate a region of hGH associated with fat metabolism while avoiding the full hormone's growth-promoting actions. Laboratory and commercial materials typically present it as a lyophilized powder for research use. Its identity is defined by amino acid sequence, not by a single brand.
In the scientific literature, AOD-9604 appears in reviews of growth hormone fragments and in discussions of peptide-based metabolic research. Some sources distinguish it from growth hormone itself, while others group it with compounds marketed for weight management. The evidence base is small compared with approved obesity medications. Questions about long-term efficacy and clinical relevance remain open, and independent replication of key findings is limited. Most published reports are early-stage and exploratory.
AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It is often described as hGH fragment 176-191. Research interest arose because it was designed to isolate possible effects on fat metabolism from other actions of growth hormone. It is not a full growth hormone molecule. Its development history includes early laboratory and animal studies followed by human trials. The peptide has been examined in laboratory, animal, and limited human studies.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic peptide | Based on the C-terminal region of human growth hormone. |
| Amino acid length | 16 residues | Often described as hGH fragment 176-191. |
| Appearance | Lyophilized powder | Typically white to off-white; exact appearance depends on grade. |
| Solubility | Soluble in water | Aqueous solubility depends on pH, ionic strength, and preparation. |
| Typical storage | -20 °C or lower | Lyophilized peptide is usually kept cold and dry; solutions may require freezing. |
Detection of AOD-9604 in biological samples relies on analytical techniques capable of distinguishing a small synthetic peptide from related endogenous sequences. Liquid chromatography coupled with tandem mass spectrometry is commonly used for confirmatory analysis. Sample preparation may involve immunoaffinity enrichment or solid-phase extraction to concentrate the peptide. Because the molecule is small and may be present at low concentrations, assay sensitivity and specificity are ongoing analytical challenges. Laboratories also validate methods against reference materials when available.
Regulatory interest in AOD-9604 increased after high-profile anti-doping cases involving peptide products. In some cases, the substance was supplied under alternative names or in compounded preparations, complicating traceability. Sports tribunals and anti-doping panels have discussed whether the peptide was explicitly banned at the time of use, leading to clarifications by the World Anti-Doping Agency. For consumers and researchers, the legal status can vary by jurisdiction, and products marketed as research chemicals may lack independent quality verification.
Clinical development of AOD9604 included trials in people with obesity, but the results did not lead to approval as a prescription medicine in major markets. Interest later shifted to research settings and to unapproved products marketed for body composition. Regulatory agencies have questioned whether the peptide qualifies as a dietary ingredient, and some have issued warnings about its presence in supplements. Long-term human safety data are limited, and questions about efficacy, dosing, and target populations remain unresolved.
AOD9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It corresponds to a short sequence near the end of the 191-amino-acid hormone, often described as residues 176–191 or a related fragment. Researchers designed it to separate metabolic effects from the growth-promoting actions of full-length growth hormone. Early work in the 1990s explored it as a candidate for weight and lipid disorders. It is not a naturally circulating hormone fragment produced in large amounts.
Clinical development of AOD-9604 included trials in people with obesity. Reports from early-phase and mid-phase studies described modest or inconsistent changes in body weight. A phase IIb program did not meet its primary endpoint, and the compound was not approved for medical use. Differences in formulation, delivery route, and participant characteristics may explain some of the variation. Later investigations explored whether the peptide might have effects in other tissues, including cartilage.
Regulatory treatment of AOD-9604 is shaped by its classification as a peptide hormone. The World Anti-Doping Agency lists it as a prohibited substance, and many national anti-doping organizations adopt that list. It does not hold approval as a prescription medicine in the United States, the European Union, or other major markets. Products sold online are frequently labeled for research use only and may not undergo independent quality testing. Import and possession rules differ by country, so legal status depends on local law.
Regulatory status varies by country. In the United States, AOD-9604 is not approved as a prescription drug. It is sometimes sold as a research chemical or dietary supplement, though such marketing may fall outside legal frameworks. The World Anti-Doping Agency prohibits its use in sport. Researchers must obtain it through legitimate suppliers and follow institutional rules. Its legal classification continues to evolve as authorities increasingly assess peptide products more broadly.
AOD-9604 is a synthetic peptide whose sequence matches the C-terminal fragment of human growth hormone, specifically residues 176 through 191. This region differs from the full hormone in its receptor interactions. The peptide is not a growth hormone secretagogue and does not bind the growth hormone receptor in the same manner. Researchers have examined it for effects on lipid metabolism, but its exact pharmacological profile remains an active area of study.
Additionally, CAM providers are concerned by the closure of other CAM laboratories under CLIA, and have sought to avoid detection. Some CAM providers and laboratory personnel have not had exposure to laboratory curriculum and are unaware of CLIA requirements. CLIA is largely reliant on laboratories to self-identify themselves for enrollment. Providers of CAM laboratories have opposed CLIA oversight and suggested they be regulated by their peers or by a CAM-specific division. CAM providers have stated that they should be exempt from CLIA since CAM laboratories do not participate in health insurance. Others claim that they are exempt from CLIA because the tests are performed solely for research purposes and not used in patient care and treatment decisions. Several pathologists have stated that CAM testing falls within the scope of their medical license and should not be regulated under CLIA. CLIA provisions are geared towards CLIA-certified laboratories, but not for those that have not enrolled. When a CAM laboratory is found to be operating without a CLIA certificate, they are sent a cease and desist letter to stop testing until the laboratory is CLIA certified. There are no administrative remedies available to CMS when a laboratory refuses to enroll in CLIA and refuses to cease testing. CMS cannot impose monetary or other administrative penalties on laboratories that defy the law, but can only refer cases to other Federal or State agencies.
== Sources == Almalki, T.M.A.; Alshammari, F.O. NURSING CARE IN RENAL FAILURE. JEC PUBLICATION. ISBN 978-93-6175-429-6. Retrieved 2025-01-21. Liu, Chenbin; Tsow, Francis; Shao, Dangdang; Yang, Yuting; Iriya, Rafael; Tao, Nongjian (2016). "Skin Mechanical Properties and Hydration Measured With Mobile Phone Camera". IEEE Sensors Journal. 16 (4): 924–930. Bibcode:2016ISenJ..16..924L. doi:10.1109/JSEN.2015.2492241. ISSN 1530-437X. Saavedra, Jose M. (1991-03-01). "Capillary Refilling (Skin Turgor) in the Assessment of Dehydration". Archives of Pediatrics & Adolescent Medicine. 145 (3): 296–298. doi:10.1001/archpedi.1991.02160030064022. ISSN 1072-4710. PMID 2003478.
==== Laser-assisted nonpenetrating deep sclerectomy ==== The most common surgical approach currently used for the treatment of glaucoma is trabeculectomy, in which the sclera is punctured to alleviate intraocular pressure. Nonpenetrating deep sclerectomy (NPDS) surgery is a similar, but modified, procedure, in which instead of puncturing the scleral bed and trabecular meshwork under a scleral flap, a second deep scleral flap is created, excised, with further procedures of deroofing the Schlemm's canal, upon which, percolation of liquid from the inner eye is achieved and thus alleviating intraocular pressure, without penetrating the eye. NPDS is demonstrated to have significantly fewer side effects than trabeculectomy. However, NPDS is performed manually and requires higher level of skills that may be assisted with instruments. In order to prevent wound adhesion after deep scleral excision and to maintain good filtering results, NPDS as with other non-penetrating procedures is sometimes performed with a variety of biocompatible spacers or devices, such as the Aquaflow collagen wick, ologen Collagen Matrix, or Xenoplast glaucoma implant. Laser-assisted NPDS is performed with the use of a CO2 laser system. The laser-based system is self-terminating once the required scleral thickness and adequate drainage of the intraocular fluid have been achieved.
==== Comparison of pharmacokinetics between dosage forms ==== The free acid (HMB-FA) and monohydrated calcium salt (HMB-Ca) forms of HMB have different pharmacokinetics. HMB-FA is more readily absorbed into the bloodstream and has a longer elimination half-life (3 hours) relative to HMB-Ca (2.5 hours). Tissue uptake and utilization of HMB-FA is 25–40% higher than for HMB-Ca. The fraction of an ingested dose that is excreted in urine does not differ between the two forms.
=== Migration === Growth and prosperity, however, did not spread evenly, leaving behind some social strata and economic sectors. The agricultural sector continued to face challenges. Between 1951 and 1991, many workers left agriculture. Mechanization reduced the need for workers. Employment fell from 8,261,000 to 1,629,000, and in particular, employment under 30 years of age plummeted from 3,299,000 in 1951 to 341,000 in 1991. In Calabria after the war, population increased, but jobs did not, leading many to migrate. The Parliamentary Commission for the Study of Misery reported that 179,500 Calabrians (37.7%) lived in a state of misery, the highest%age in Ital, compared to 1.5% in the North, 5.9% in the center and the larger Mezzogiorno (28.3%) and attributed this to the land's unstable hydrogeology, lack of infrastructure, the demanding climate, but mostly unemployment. In the decade between 1951 and 1961 as many as 400,000 Calabrians migrated, especially to America and Northern Italy, particularly those concentrated in Italy's industrial triangle, where population increased (Turin (+43%) and Milan (+24%). Calabrians also moved from inland areas to coastal centers, again to seek work in construction, urban services, and commerce. Many inland rural areas were abandoned. One e..xample is the medieval village of Badolato Superiore, near Soverato, which became a “metaphor of the abandonment, ruin, flight, and hope of all of Calabria, of the entire Mezzogiorno”.
Sources: en.wikipedia.org
Salcaprozate sodium (SNAC) is an intestinal permeation enhancer that is used in drug formulations particularly for macromolecules and poorly permeable compounds. SNAC has been used in formulations of drugs that have undergone clinical trials and has achieved generally recognized as safe (GRAS) status, with U.S. Food and Drug Administration approval for use in a medical food products. An oral formulation of semaglutide that includes SNAC has been approved for human use in the United States and Europe.
=== Fertility support === Progesterone is used for luteal support in assisted reproductive technology (ART) cycles such as in vitro fertilization (IVF). It is also used to correct luteal phase deficiency to prepare the endometrium for implantation in infertility therapy and is used to support early pregnancy.
Her parents divorced when she was 12. Schumer moved to Long Island with her mother and lived in Rockville Centre where she attended South Side High School. She was voted both "Class Clown" and "Teacher's Worst Nightmare" upon graduation in 1999. She attended the Hebrew school of the Central Synagogue of Nassau County, a Reform synagogue in Rockville Centre, where her mother served on the school's board. After graduating from high school, Schumer attended Towson University in Towson, Maryland, where she graduated with a degree in theater in 2003. After graduating from college, she returned to New York City, where she studied at the William Esper Studio for two years and worked as a bartender and a waitress. She also lived with her boyfriend in Santa Barbara, California, where she worked as a pedicab driver. She has a younger sister, Kim Caramele, who is a comedy writer and a producer, and a half-brother, Jason Stein, who is a musician in Chicago, Illinois.
==== Segments ==== The primary bronchi enter the lungs at the hilum and initially branch into secondary bronchi also known as lobar bronchi that supply air to each lobe of the lung. The lobar bronchi branch into tertiary bronchi also known as segmental bronchi and these supply air to the further divisions of the lobes known as bronchopulmonary segments. Each bronchopulmonary segment has its own (segmental) bronchus and arterial supply. Segments for the left and right lung are shown in the table. The segmental anatomy is useful clinically for localising disease processes in the lungs. A segment is a discrete unit that can be surgically removed without seriously affecting surrounding tissue.
Sources: en.wikipedia.org
Immediately after the 17th Party Congress, Xi was elected by the first plenary session of the 17th Central Committee to be the 6th-ranking member of the Politburo Standing Committee on 22 October 2007. In addition, Xi became a member of the 17th Secretariat. He also led the Central Leading Group for Party Building and the Central Hong Kong and Macau Affairs Leading Group, as well as being the deputy leader of the Central Foreign Affairs Leading Group. He was ranked above Li Keqiang in the PSC, an indication that he was going to succeed Hu Jintao as China's next leader. This assessment was further supported at the first session of the 11th National People's Congress in March 2008, when Xi was elected as vice president of China. Following his elevation, Xi held a broad range of portfolios. He was put in charge of the comprehensive preparations for the 2008 Summer Olympics in Beijing, as well as being the central government's leading figure in Hong Kong and Macau affairs. In addition, he also became the president of the Central Party School, the CCP's cadre-training and ideological education school. In the wake of the 2008 Sichuan earthquake, Xi visited Shaanxi, which was also hit by the earthquake. After the Olympics, Xi was assigned the post of committee chair for the preparations of celebrations for the 60th anniversary of the People's Republic of China. He was also reportedly at the helm of a top-level CCP committee dubbed the 6521 Project, which was charged with ensuring social stability during a series of politically sensitive anniversaries in 2009.
== NPU foundations == C-NPU has been managing the development of structured definitions for laboratory result information for the IFCC and IUPAC and making recommendations through papers, recommendations, and technical reports. These mostly joint documents are available from the old IUPAC website [Y].
== Adverse effects == Its most common adverse effects are transient nausea and vomiting, dizziness, drowsiness, fatigue, headache, and nervousness; less commonly, nausea and vomiting (after repeated dosing), hallucinations, confusion, euphoria, tremor, hyperreflexia, clonus, and increased sweating. Uncommonly, somnolence; rarely, diarrhoea and abdominal pain.
== Sources == This article incorporates text from a free content work. Licensed under CC BY-SA 3.0 (license statement/permission). Text taken from The State of Food and Agriculture 2019. Moving forward on food loss and waste reduction, In brief, 24, FAO, FAO.
=== Kazuko's family === Yasuko Tomita as Mine Hosoki, Kazuko's mother. Gaku Hosokawa as Hisao Hosoki, Kazuko's younger brother and later business associate. Erika Shumoto as Akiko Hosoki, Kazuko's sister. Miho Kanazawa as Sachiko Hosoki, Kazuko's sister.
Sources: en.wikipedia.org
It is a synthetic peptide based on a C-terminal fragment of human growth hormone. It is commonly referred to as hGH fragment 176-191 and is studied for metabolic effects rather than growth effects.
No. It represents only a short portion of the hGH sequence and lacks the full hormone's structure. As a result, its biological activity and regulatory status differ from those of prescription hGH.
The exact peptide is not typically described as a circulating hormone; it is a synthetic construct based on a natural sequence. Fragments of hGH can exist in laboratory or metabolic contexts, but AOD-9604 itself is manufactured for research.
It is a synthetic peptide fragment derived from the C-terminal region of human growth hormone, commonly referred to as hGH fragment 176-191. It has been investigated for effects on fat metabolism, but it is not an approved medication in most jurisdictions.